Biotricity Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für Biotricity zu prognostizieren.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Healthcare Services Gewinnwachstum	26.9%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	05 Mar 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:BTCY - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2025	14	N/A	N/A	N/A	1
3/31/2024	12	-15	-7	-7	N/A
12/31/2023	12	-15	-7	-7	N/A
9/30/2023	11	-17	-9	-9	N/A
6/30/2023	11	-18	-11	-11	N/A
3/31/2023	10	-20	-14	-14	N/A
12/31/2022	9	-21	-16	-16	N/A
9/30/2022	9	-23	-18	-18	N/A
6/30/2022	8	-29	-17	-17	N/A
3/31/2022	8	-30	-15	-15	N/A
12/31/2021	7	-30	-14	-14	N/A
9/30/2021	6	-27	-12	-12	N/A
6/30/2021	5	-19	-11	-11	N/A
3/31/2021	3	-16	-11	-11	N/A
12/31/2020	3	-16	-10	-10	N/A
9/30/2020	2	-14	-10	-10	N/A
6/30/2020	2	-13	-9	-9	N/A
3/31/2020	1	-11	-8	-8	N/A
12/31/2019	1	-8	-6	-6	N/A
9/30/2019	1	-8	-5	-5	N/A
6/30/2019	1	-8	-5	-5	N/A
3/31/2019	0	-9	-5	-5	N/A
12/31/2018	0	-10	-6	-6	N/A
9/30/2018	0	-9	-5	-5	N/A
6/30/2018	0	-9	-5	-5	N/A
3/31/2018	N/A	-9	-5	-5	N/A
12/31/2017	N/A	-8	N/A	-5	N/A
9/30/2017	N/A	-8	N/A	-5	N/A
6/30/2017	N/A	-9	N/A	-4	N/A
3/31/2017	N/A	-8	N/A	-4	N/A
12/31/2016	N/A	-7	N/A	-2	N/A
9/30/2016	N/A	-6	N/A	-2	N/A
6/30/2016	N/A	-5	N/A	-2	N/A
3/31/2016	N/A	-5	N/A	-2	N/A
12/31/2015	N/A	-5	N/A	-2	N/A
9/30/2015	N/A	-4	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von BTCY über der Sparquote liegt (2.4%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von BTCY schneller wachsen werden als der Markt US

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von BTCY in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von BTCY schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von BTCY schneller wachsen werden als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von BTCY in 3 Jahren voraussichtlich hoch sein wird

Biotricity Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Biotricity, Inc. Provides Earnings Guidance for the First Fiscal Quarter Ended June 30, 2023

Consensus revenue estimates fall by 19%

Price target decreased to US$3.83

Biotricity, Inc. Announces Earnings Guidance for the Fiscal 2022

Recent updates

Biotricity, Inc. Launches Direct-To-Consumer Heart Health Screening Service, Heartsecure, Making Heart Health Services

Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $2.684644 million.

Biotricity Inc. Announces High Demand for Its Latest Device, Biotres Pro

Biotricity, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.55 million.

Nasdaq Notifies Biotricity That the Nasdaq Hearings Panel Grants Its Request to Continue Its Listing on Nasdaq

Biotricity, Inc. announced that it has received $2 million in funding

Biotricity Announces Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities

Biotricity, Inc. announced a financing transaction

Biotricity Unveils That Improved Margins Resulted from Latest Advancements to Its Proprietary Cardiac Ai Cloud Platform and Announces Plans for Continued Expansion of Its Cardiac AI Cloud

Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $10.55 million.

Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $10.55 million.

Biotricity, Inc. announced delayed 10-Q filing

Biotricity, Inc. Receives A Delisting Determination Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Investors Give Biotricity, Inc. (NASDAQ:BTCY) Shares A 38% Hiding

Biotricity Inc. Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 Billion Heartbeats

New major risk - Share price stability

Second quarter 2024 earnings released: US$0.44 loss per share (vs US$0.57 loss in 2Q 2023)

Biotricity, Inc. to Report Q2, 2024 Results on Nov 14, 2023

Biotricity Releases Another Groundbreaking Product: Biotres Pro

New major risk - Market cap size

Many Still Looking Away From Biotricity, Inc. (NASDAQ:BTCY)

Biotricity Continues to Expand Patent Portfolio with Latest Patent Filing for Bioheart Device

Biotricity, Inc. Announces Patent Filing for Cutting-Edge Biotres Device

Biotricity, Inc. has completed a Follow-on Equity Offering.

New major risk - Financial position

First quarter 2024 earnings released: US$0.069 loss per share (vs US$0.59 loss in 1Q 2023)

Biotricity Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Market Value of Listed Securities Requirement

Biotricity Inc. Expands Its Proprietary AI Model and Deepens Relationship with Amazon Aws and Google's Tensor Flow for Remote Cardiac Care Applications

Biotricity Regains Nasdaq Listing Compliance

Biotricity, Inc. Provides Earnings Guidance for the First Fiscal Quarter Ended June 30, 2023

Full year 2023 earnings released: US$0.38 loss per share (vs US$0.67 loss in FY 2022)

Third quarter 2023 earnings: Revenues exceed analyst expectations

Biotricity Receives A Letter from Nasdaq Capital Market Regarding Minimum Bid Price

Consensus revenue estimates fall by 19%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$3.83

Less than half of directors are independent

Biotricity, Inc. Launches Cardiac Disease Management Solution Following 2 Successful Pilots with Oklahoma & Kentucky Clinics

Less than half of directors are independent

Biotricity GAAP EPS of -$0.09, revenue of $2.06M

Biotricity Announces Management Changes

Biotricity, Inc.: A First Take

Biotricity, Inc. announced delayed annual 10-K filing

Is Biotricity (NASDAQ:BTCY) Using Debt In A Risky Way?

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Biotricity, Inc. to Report Q3, 2022 Results on Feb 14, 2022

High number of new directors

Does Biotricity (NASDAQ:BTCY) Have A Healthy Balance Sheet?

High number of new directors

Biotricity: Capital Raise Leads To Buying Opportunity

Biotricity Common Stock Deleted from Other OTC

Biotricity, Inc. announced delayed 10-Q filing

Biotricity, Inc. Announces Earnings Guidance for the Fiscal 2022

Biotricity, Inc. to Report Q3, 2021 Results on Feb 11, 2021

Biotricity, Inc. announced that it has received $9.5575 million in funding

Biotricity Announces New Solution for Personal Heart Management with Bioheart

Biotricity, Inc. Prepares 510(k) FDA Filing for Biotres

Biotricity Inc. Announces Launch of Its Bioflux® Direct Program

Biotricity, Inc. announced a financing transaction

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken